Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11580466 | 0.75 | DUT (0.42) | DUT | |
| SCHEMBL5361132 | 0.74 | — | — | |
| SCHEMBL370773 | 0.73 | DUT (0.30) | DUT | |
| SCHEMBL2224327 | 0.72 | — | — | |
| SCHEMBL5081792 | 0.71 | TSHR (0.31) | — | |
| SCHEMBL8063404 | 0.71 | DUT (0.43) | DUT | |
| SCHEMBL18776208 | 0.71 | — | — | |
| SCHEMBL5694165 | 0.71 | — | — | |
| SCHEMBL211972 | 0.71 | — | — | |
| SCHEMBL851426 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20260098009-A1 | Process for the Production of Specialty Mercaptans From the C4 Oligomerization Product | IndianOil Corporation Limited (IN) | 2026-04-09 | — | — | US | disclosed |
| US-20260098009-A1 | Process for the Production of Specialty Mercaptans From the C4 Oligomerization Product | IndianOil Corporation Limited (IN) | 2026-04-09 | — | — | US | disclosed |
| US-12528839-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | VERIMMUNE, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388617-A1 | DOUBLE-STRANDED RNA COMPRISING NUCLEOTIDE ANALOG CAPABLE OF REDUCING OFF-TARGET TOXICITY | RONA BIOSCIENCE, LIMITED (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250368675-A1 | CYCLIC PHOSPHONATE-MODIFIED NUCLEOTIDE | RONA BIOSCIENCE, LIMITED (CN) | 2025-12-04 | — | — | US | disclosed |
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| US-12344637-B2 | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer | VERIMMUNE INC. | 2025-07-01 | — | — | US | disclosed |
| WO-2025087397-A1 | LIGANDS FOR EXTRAHEPATIC DELIVERY OF siRNA | RONA BIOSCIENCE, LIMITED (CN) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025082491-A1 | TARGETED DELIVERY LIGAND | 成都新泽利医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160031869-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-04 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2800750-A1 | CARBOCYCLIC NUCLEOSIDES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Cellceutix Corporation (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| WO-2013103601-A1 | CARBOCYCLIC NUCLEOSIDES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CELLCEUTIX CORPORATION (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-6060207-A | LOW IN ABSORPTION OF A LIGHT SOURCE OF SHORT WAVELENGTH AND EXCELLENT IN DRY ETCH RESISTANCE; COMPRISES A COMPOUND HAVING A TERPENOID SKELETON | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | DUT 183/4885 |
| US-20260098009-A1 | Process for the Production of Specialty Mercaptans From the C4 Oligomerization Product | TMT1A, TST, SSR4 | DUT 4030/4885 |
| US-20250388617-A1 | DOUBLE-STRANDED RNA COMPRISING NUCLEOTIDE ANALOG CAPABLE OF REDUCING OFF-TARGET TOXICITY | NSUN2, NSUN3, RNGTT | DUT 228/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | DUT 1013/4885 |
| US-20160031869-A1 | NOVEL INHIBITORS | GLS, GLUL, QPCT | DUT 1948/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | DUT 1013/4885 |
| US-12528839-B2 | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | KLK3, KLKB1, CTSV | DUT 2163/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | DUT 1013/4885 |
| US-20250368675-A1 | CYCLIC PHOSPHONATE-MODIFIED NUCLEOTIDE | PNKP, NT5C3B, ENPP1 | DUT 25/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | DUT 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.